Business Daily from THE HINDU group of publications
Friday, Mar 13, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Regulatory Bodies & Rulings
Aurobindo gets nod for HIV drug

Hyderabad, March 12

Aurobindo Pharma Ltd has received tentative approval for Lopinavir/Ritonavir tablets used in the treatment of HIV- I infection from the US Food and Drug Administration. The tablets are the generic equivalent of Abbott Laboratories' Kaletra tablets and falls under the anti retroviral (ARV) segment. They are indicated in combination with other ARV agents for trating HIV-I in adults and children above two years, the Hyderabadbased company said in a release. - Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
The Accord variant

TVS Motor converts loan to subsidiary to equity
NCC bags contract worth Rs 263 cr
EMCO bags 5 orders from PGCIL
Chennai co drags DG Shipping to court on foreign vessel charter licence issue
Bharti Airtel makes top level changes
Sodexo poised to become India’s largest food services player
Delhi HC rejects petition on Satyam
RIL may start gas production from KG field next week
Aurobindo gets nod for HIV drug
Kochi port signs pact with Petronet for LNG terminal
Tata Comm to invest $500 m next fiscal
Piramal keen on expanding pharma portfolio
‘Strides Arcolab to launch over 25 products this year’
Infiniti Retail to open 20 more Croma stores
Aircel to invest $1 b in expansion this year
No benefits to Tata Motors from UK Govt aid to JLR


Life
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line